AMD diagnostic imaging
Patients are unaware they have a ticking time bomb in their eyes


Sean Henahan
Published: Tuesday, March 28, 2017

Patients are unaware they have a ticking time bomb in their eyesICG angiography Why not use ICG angiography to follow patients? That approach is expensive, invasive, time consuming, resource intensive, and until recently, such cases didn't have an intervention, he noted. Rather, Dr Rosenfeld and colleagues used a novel swept source OCT angiography system to look for subclinical CNV. The prototype from Carl Zeiss Meditec performed a 3mm X 3mm rraster scan centered on the fovea and repeated each B-scan 4 times, with 300 A-scans per B-scan, and 300 B-scan positions, for a total of 360,000 A-scans. Using a special decorrelation algorithms, the B-scans were compiled to provide en face flow images of the retina and choroid. The optical microangiographic approach known as OMAG provided provided the microvascular flow information and different layers were segmented, which included the whole retina, the inner or superficial retina layer or plexus, the middle or deep retinal plexus, and the outer avascular retinal layer. Another layer from the outer retinal layer to the choriocapillaris, known as the ORCC layer, was also created since this is where most of the choroidal neovascularization can be found. Subsequent clinical research (Ophthalmology, Roisman et al, Volume 123, Issue 6, 1309–1319) confirmed that the system could detect CNV lesions before they started leaking. Subsequent follow-up of 103 patients with wet AMD in one eye and dry AMD in the other revealed a prevalence of about 18% for these subclinical lesions, with an estimated rate of conversion to exudation of about 16% at one year, but longer follow-up is underway. “This is a new stage of non-exudative AMD. We call it non-exudative neovascular AMD. I think we can find these patients easily with SS-OCTA and we need to follow them closely. Ongoing studies are looking at prevalence, incidence, and onset of exudation. For now, in addition to close follow-up, we do not recommend anti-VEGF treatment,” he concluded. “I never treat asymptomatic patients. I educate my patients, I emphasize the need for vision monitoring at home, and I enlist them to be stewards of their own vision. In addition, if we start treatment in the absence of fluid, what’s our endpoint?,” Rosenfeld stated. prosenfeld@med.miami.edu
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.